ANN ARBOR STAGE III NON-HODGKIN LYMPHOMA
Clinical trials for ANN ARBOR STAGE III NON-HODGKIN LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new ANN ARBOR STAGE III NON-HODGKIN LYMPHOMA trials appear
Sign up with your email to follow new studies for ANN ARBOR STAGE III NON-HODGKIN LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Could adding vorinostat to standard chemo beat tough lymphoma?
Disease control OngoingThis study tests whether adding a drug called vorinostat to the standard R-CHOP chemotherapy regimen can better treat newly diagnosed, advanced-stage diffuse large B-cell lymphoma (DLBCL). Vorinostat works by blocking enzymes that help cancer cells grow and by cutting off their b…
Matched conditions: ANN ARBOR STAGE III NON-HODGKIN LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 23, 2026 11:59 UTC
-
New drug combo shows promise for Hard-to-Treat cancers
Disease control OngoingThis early-phase study tests a new drug (veliparib) combined with two chemotherapy drugs (cyclophosphamide and doxorubicin) in people with advanced solid tumors or non-Hodgkin lymphoma that cannot be removed by surgery or have spread. The main goal is to find the safest dose and …
Matched conditions: ANN ARBOR STAGE III NON-HODGKIN LYMPHOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 17, 2026 12:04 UTC
-
Can DNA tests pick the right cancer drug for kids?
Knowledge-focused OngoingThis study screens children and teens with advanced solid tumors, lymphomas, or histiocytic disorders to find genetic changes in their cancer cells. Participants undergo biopsies and scans to identify mutations that can be targeted by specific drugs. The goal is to see if matchin…
Matched conditions: ANN ARBOR STAGE III NON-HODGKIN LYMPHOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Jun 23, 2026 21:02 UTC